ArticleiScience2021
Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates.
Open access · goldAbstract read
In one paragraph
Article in iScience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 30 citations in OpenAlex.
- Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk.The Journal of infectious diseases · 2022Trial
- Preferential engagement of the anti-inflammatory ATP/adenosine axis by HIV vaccine candidate with V1-deleted envelope in male rhesus macaques.Cell reports. Medicine · 2026Article
- Sustained mucosal delivery of SAMT-247 via an intravaginal ring reduces the risk of SIVCell reports. Medicine · 2026Article
- Friend or foe: divergent immunomodulatory effects of metabolites derived from the virucidal zinc finger inhibitor SAMT-247.Frontiers in immunology · 2026Article
- HIV vaccine candidate ΔV1gp120 formulated in ALFQA adjuvant augments mucosal immunity in female macaques.Nature communications · 2025Article
- Online Conference "Chronic Viral Infections and Cancer, Openings for Vaccines and Cure" VIRCAN2024, Monitoring the Progress.Vaccines · 2025Article
- Enhancing functional antibody responses against HIV envelope V1V2 through vaccine formulations.Frontiers in immunology · 2025Article
- Immunogenicity and protection mediated by dmLT and alum adjuvants for an HIV-1 vaccine.Frontiers in immunology · 2025Article
- Loss of HIV candidate vaccine efficacy in male macaques by mucosal nanoparticle immunization rescued by V2-specific response.Nature communications · 2024Article
- Contemporary HIV-1 consensus Env with AI-assisted redesigned hypervariable loops promote antibody binding.Nature communications · 2024Article
- A remarkable genetic shift in a transmitted/founder virus broadens antibody responses against HIV-1.eLife · 2024Article
- Potent antibody-dependent cellular cytotoxicity of a V2-specific antibody is not sufficient for protection of macaques against SIV challenge.PLoS pathogens · 2024Article
- Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.Frontiers in immunology · 2024Article
- In Vivo Treatment with Insulin-like Growth Factor 1 Reduces CCR5 Expression on Vaccine-Induced Activated CD4Vaccines · 2023Article
- Proceedings of the Online Conference "Vaccines and Vaccination during and Post COVID Pandemics" (7-9 December 2022).Vaccines · 2023Article
- Vaccine plus microbicide effective in preventing vaginal SIV transmission in macaques.Nature microbiology · 2023Article
- HIV vaccine candidate plus microbicide decreases SIV infection risk by more than 90.Nature microbiology · 2023Article
- Antibody-dependent cellular cytotoxicity, infected cell binding and neutralization by antibodies to the SIV envelope glycoprotein.PLoS pathogens · 2023Article
- HIV vaccine candidate efficacy in female macaques mediated by cAMP-dependent efferocytosis and V2-specific ADCC.Nature communications · 2023Article
- Cholera toxin B scaffolded, focused SIV V2 epitope elicits antibodies that influence the risk of SIVFrontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
58 authors at 8 institutions in 1 country.
Isabela Silva de CastroAnimal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD 20892, USA.
Giacomo GoriniAnimal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD 20892, USA.
Rosemarie MasonImmunoTechnology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Jason GormanStructural Biology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Massimiliano BissaAnimal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD 20892, USA.
Mohammad A RahmanImmune Biology of Retroviral Infection Section, National Cancer Institute, Bethesda, MD 20892, USA.
Anush ArakelyanSection on Intercellular Interactions, Eunice Kennedy-Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA.
Irene KaliszAdvanced Bioscience Laboratories, Rockville, MD 20850, USA.
Stephen WhitneyAdvanced Bioscience Laboratories, Rockville, MD 20850, USA.
Manuel Becerra-FloresNew York University School of Medicine, NYU Langone Health, New York, NY 10016, USA.
Eric NiNew York University School of Medicine, NYU Langone Health, New York, NY 10016, USA.
Kristina PeachmanHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA.
Hung V TrinhHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA.
Michael ReadU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
Mei-Hue LiuLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Donald Van RykLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Dominic Paquin-ProulxHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA.
Zhanna ShubinHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA.
Marina TuyishimeDivision of Surgical Sciences, Duke University School of Medicine, Durham, NC 27701, USA.
Jennifer PeeleDivision of Surgical Sciences, Duke University School of Medicine, Durham, NC 27701, USA.
Mohammed S AhmadiStructural Biology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Raffaello VerardiStructural Biology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Juliane HillImmunoTechnology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Margaret BeddallImmunoTechnology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Richard NguyenImmunoTechnology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
James D StamosAnimal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD 20892, USA.
Dai FujikawaAnimal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD 20892, USA.
Susie MinLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Luca SchifanellaAnimal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD 20892, USA.
Monica VaccariAnimal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD 20892, USA.
Veronica GalliAnimal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD 20892, USA.
Melvin N DosterAnimal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD 20892, USA.
Namal P M LiyanageAnimal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD 20892, USA.
Sarkis SarkisAnimal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD 20892, USA.
Francesca CaccuriAnimal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD 20892, USA.
Celia LaBrancheDivision of Surgical Sciences, Duke University School of Medicine, Durham, NC 27701, USA.
David C MontefioriDivision of Surgical Sciences, Duke University School of Medicine, Durham, NC 27701, USA.
Georgia D TomarasDuke Human Vaccine Institute, Duke University, Durham, NC 27701, USA.
Xiaoying ShenDuke Human Vaccine Institute, Duke University, Durham, NC 27701, USA.
Margherita RosatiHuman Retrovirus Section, National Cancer Institute, Frederick, MD 21702, USA.
Barbara K FelberHuman Retrovirus Pathogenesis Section, National Cancer Institute, Frederick, MD 21702, USA.
George N PavlakisHuman Retrovirus Section, National Cancer Institute, Frederick, MD 21702, USA.
David J VenzonBiostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
William MagnanelliAIDS and Cancer Virus Program, Leidos Biomedical Research Inc., Frederick National Laboratory, Frederick, MD 21704, USA.
Matthew BreedAIDS and Cancer Virus Program, Leidos Biomedical Research Inc., Frederick National Laboratory, Frederick, MD 21704, USA.
Josh KramerAIDS and Cancer Virus Program, Leidos Biomedical Research Inc., Frederick National Laboratory, Frederick, MD 21704, USA.
Brandon F KeeleAIDS and Cancer Virus Program, Leidos Biomedical Research Inc., Frederick National Laboratory, Frederick, MD 21704, USA.
Michael A EllerHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA.
Claudia CicalaLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
James ArthosLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Guido FerrariDivision of Surgical Sciences, Duke University School of Medicine, Durham, NC 27701, USA.
Leonid MargolisSection on Intercellular Interactions, Eunice Kennedy-Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA.
Marjorie Robert-GuroffImmune Biology of Retroviral Infection Section, National Cancer Institute, Bethesda, MD 20892, USA.
Peter D KwongStructural Biology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Mario RoedererImmunoTechnology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Mangala RaoU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
Timothy J CardozoNew York University School of Medicine, NYU Langone Health, New York, NY 10016, USA.
Genoveffa FranchiniAnimal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD 20892, USA.
National Cancer Institute · USNational Institutes of Health · USDuke University · USHenry M. Jackson Foundation · USLeidos (United States) · USNew York University · USAdvanced Bioscience Laboratories (United States) · USWalter Reed Army Institute of Research · US
Funding
Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4MPreventive Vaccines for HIVZIABC011126 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FRANCHINI, GENOVEFFA · 2009 to 2025
$55.3MPhase I HIV vaccine trial with DNAALVAC-HIV gp120 delta V1 vaccinesZIABC012025 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FRANCHINI, GENOVEFFA · 2021 to 2025
$35.6MPrevention of AIDSZIABC010350 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FELBER, BARBARA K · 2009 to 2025
$30.0MImmunotherapeutic Approaches for AIDSZIABC010749 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PAVLAKIS, GEORGE N. · 2009 to 2022
$21.6MDesign Of ImmunogensZIAAI005024 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ZHOU, TONGQING · 2009 to 2025
$21.5MOffice of Collaborative BiostatisticsZIDSC007202 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI CHOO-WOSOBA, HYOYOUNG · 2009 to 2025
$14.5MInteraction of HIV envelope with cell surface receptorsZIAAI000883 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ARTHOS, JAMES L · 2009 to 2024
$14.0MViral transmission and pathogenesis in human tissuesZIAHD008968 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI MARGOLIS, LEONID B. · 2018 to 2023
$12.2MRuth L. Kirschstein National Research Service Award (NRSA)- T32T32AI007392 · NIAID · DUKE UNIVERSITY · PI Amy Lynn Corneli, Guido Ferrari · 1990 to 2026
$9.8MCombined cocaine and HIV vaccineDP1DA036478 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CARDOZO, TIMOTHY J · 2013 to 2017
$4.7MStructure-Based Characterization of gp120 Non-V3 Variable Loop EpitopesR01AI084119 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CARDOZO, TIMOTHY J, KONG, XIANGPENG · 2009 to 2014
$3.2MCCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENIAID NIH HHS R01 AI084119NIAID NIH HHS T32 AI007392NIDA NIH HHS DP1 DA036478NIH HHS P51 OD011104
Abstract
The efficacy of ALVAC-based HIV and SIV vaccines in humans and macaques correlates with antibodies to envelope variable region 2 (V2). We show here that vaccine-induced antibodies to SIV variable region 1 (V1) inhibit anti-V2 antibody-mediated cytotoxicity and reverse their ability to block V2 peptide interaction with the α
Indexed as
Immunologymolecular structurevirology
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.